BMS-986179 + nivolumab

**BMS-986179 + nivolumab** is a combination investigational immunotherapy regimen for advanced solid tumors. BMS-986179 is a monoclonal antibody targeting and inhibiting CD73, an ectoenzyme that produces adenosine in the tumor microenvironment, which suppresses anti-tumor immune activity. By blocking CD73, BMS-986179 aims to reduce adenosine-mediated immune suppression and enhance immune system recognition and destruction of tumor cells. **Nivolumab** is an anti-PD-1 monoclonal antibody checkpoint inhibitor—approved as "Opdivo"—that reactivates exhausted T cells by blocking the programmed death-1 (PD-1) pathway. This combination was tested in a Phase 1/2 clinical trial for patients with advanced or metastatic solid tumors, with a focus on safety and anti-tumor efficacy[1][2][3][5].

Other names

anti-CD73 + nivolumab